Cardiac rehabilitation programs in left ventricular systolic dysfunction: do these programs reduce the number of patients requiring an implantable cardioverter defibrillator?
FDA expedited access pathway enables staged approval opportunity for baroreflex activation therapy for heart failure with reduced ejection fraction: the BeAT-HF trial